Alpha Centric Advisors LLC Uni Qure N.V. Transaction History

Alpha Centric Advisors LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 24, 2024	BUY	$4.82 - $6.93 $187,859 - $270,096	38,975 Added 9.26%	460,000 $2.39 Million
Q4 2023 Feb 14, 2024	BUY	$5.63 - $8.27 $166,225 - $244,171	29,525 Added 7.54%	421,025 $2.85 Million
Q3 2023 Nov 13, 2023	BUY	$6.71 - $11.83 $2.31 Million - $4.07 Million	344,000 Added 724.21%	391,500 $2.63 Million
Q2 2023 Aug 08, 2023	BUY	$11.12 - $22.2 $528,200 - $1.05 Million	47,500 New	47,500 $544,000
Q2 2021 Mar 09, 2022	SELL	$29.97 - $37.17 $974,025 - $1.21 Million	-32,500 Closed	0 $0
Q1 2021 Mar 09, 2022	BUY	$29.24 - $42.03 $804,100 - $1.16 Million	27,500 Added 550.0%	32,500 $1.1 Million
Q4 2020 Mar 11, 2022	BUY	$35.35 - $50.67 $106,050 - $152,010	3,000 Added 150.0%	5,000 $181,000
Q3 2020 Mar 11, 2022	BUY	$35.98 - $47.66 $51,271 - $67,915	1,425 Added 247.83%	2,000 $74,000
Q2 2020 Mar 11, 2022	BUY	$45.06 - $67.74 $25,909 - $38,950	575 New	575 $26,000

153

41M

925K

617K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $289M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Alpha Centric Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Alpha Centric Advisors LLC with notifications on news.